Posts tagged rare diseases
Eiger BioPharma names Dr. David Apelian as COO, EMO

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.

Read More
HCW starts Pharming at buy

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. 

Read More
Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More
HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday.

“Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively low clinical and regulatory risk,” writes analyst Andrew Fein.

Read More